Study of Rituximab to Treat Chronic Renal Transplant Rejection | Recruiting
Study of Rituximab to Treat Chronic Renal Transplant Rejection
RituxiCAN-C4
Trial Source

There is no location for this trial

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Health Conditions
  • Kidney Transplantation
  • Graft Rejection
  • Immunosuppression
Anthony Dorling, PhD, FRCP
+44 7188 5880
See all trial contact details
Primary Contact Details
Recruiting
Recruitment Status
NCT00476164
Primary Trial ID Number
Summary
Purpose of clinical trial; Evaluate the effectiveness of rituximab in C4d+ CAN Primary objective; To determine whether anti-CD20 therapy can stabilize or improve renal function and/or proteinuria in patients with C4d+, chronic (humoral) rejection in whom standard therapeutic approaches have failed. Secondary objective (s); - To compare patient and graft survival between control and rituximab-treated groups - To evaluate the adverse effect profile of rituximab in this group - To correlate changes in circulating B cell numbers, anti-HLA and non-HLA Ab profiles and titre with responses to standard therapy and / or rituximab - To correlate changes in T cell responsiveness to alloantigens with responses to standard therapy and / or rituximab Study Design; Prospective, randomised, two arm, open-labeled Study Endpoints; Primary - Rate of deterioration in renal function, defined by slope of reciprocal creatinine plot, on samples taken 3-5 months post-randomisation. - Change in degree of proteinuria, where present, at 3-5 months post-randomisation 2˚ endpoints, determined at 3-5 months post-randomisation and at 1, 2 and 3 years post-recruitment are; - Rate of deterioration in renal function, defined by slope of reciprocal creatinine plot, determined by analysis of samples taken since previous assessment. - Patient survival - Graft survival - Incidence of culture positive infection - Incidence of malignancy - Degree of proteinuria - Changes in circulating CD20+ cells in peripheral blood - Changes in anti-graft Ab titres, (measured every 3 months) - Changes in T cell responsiveness to alloantigens (measured every 3 months). Sample Size; 15 patients to be randomised to each arm (i.e. 30 patients randomised). Up to 120 patients will need to be enrolled into the study. In addition, in those participants that received a living donor kidney, these donors will be approached to provide up to 5 samples of blood to help with the in vitro analyses. Summary of eligibility criteria; - Male or female renal allograft recipients 18-70 years of age - more than 6/12 post-transplantation - Either deteriorating allograft function on reciprocal creatinine plot or significant proteinuria or both. - C4d+/- CAN on renal allograft biopsy Investigational medicinal product and dosage; Rituximab, 1g on day 0 and 1g on day 14 Active comparator product(s); None Route(s) of administration; Intravenous infusion Maximum duration of treatment of a subject; 14 days with rituximab. The treatment arms of the study, including optimisation period, formal run-in and post-randomisation phase lasts for 10 months post-recruitment. Procedures; Screening & enrollment. Potentially eligible patients will be identified by screening renal allograft biopsies performed for 'creeping creatinine' and/or proteinuria. Recruitment by informed consent prior to enrollment. Procedures; Baseline. In addition to routine tests, blood for anti-HLA and non-HLA antibody analysis and for peripheral blood mononuclear cell (PBMC) purification. Procedures; Treatment period. 3 month run-in period on optimal conventional immunosuppressive therapy, preceded by up to 2 months to allow tailored-optimization. Patients will be reviewed at least six times in their normal transplant clinic appointments for routine blood biochemistry, full blood count and urine analysis. At the end of the run-in period, further blood will be taken for anti-graft antibody analysis and PBMC purification. Those patients in whom allograft function stabilises and/or proteinuria improves will have normal transplant clinic follow-up appointments and have blood taken for further anti-graft antibody and PBMC purification up to every 3 months for 3 years. Those with continued deterioration in either allograft function or persisting or worsening proteinuria will be randomised. These patients will be reviewed during their normal transplant clinic appointments until the primary end-point and will need to have at least 6 routine blood biochemistry, full blood count and urine analysis during the final 3 months of this period, post-randomisation. At the primary end-point, further blood will be taken for anti-graft antibody analysis and PBMC. Procedures; End of Study. •Follow up will continue for 3 years, with blood taken for anti-graft antibody analysis and PBMC purification every three months Procedures for safety monitoring during trial; Regular patient interviews and examination, routine haematological and biochemical analyses. Serious adverse events will be reported and forwarded to the sponsor, MHRA, LREC and Roche as appropriate The WLRATC transplant research committee will discuss the trial and any safety concerns at their regular three monthly meetings. Data will be reviewed after 30 and also after 60 people have been enrolled. Criteria for withdrawal of patients on safety grounds; Serious adverse effects related to rituximab infusion
Research Details
    Sorry, this information is not available
Phase
Phase 4
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Study Type
Interventional
Intervention
Drug : Rituximab, Other : Control arm

Study Arm Groups : Rituximab, 2

Intervention Type
See Interventions above
Primary Outcome Measures
  • Rate of deterioration in renal function, defined by slope of reciprocal creatinine plot; 3-5 months post-randomisation; Change in degree of proteinuria, where present; 3-5 months post-randomisation
Secondary Outcome Measures
  • Rate of deterioration in renal function, defined by slope of reciprocal creatinine plot, determined by analysis of samples taken since previous assessment; 1, 2 and 3 years post-recruitment; Patient survival; 5 months post-randomisation and at 1, 2 and 3 years post-recruitment; Graft survival; 5 months post-randomisation and at 1, 2 and 3 years post-recruitment; Incidence of culture positive infection; 5 months post-randomisation and at 1, 2 and 3 years post-recruitment; Incidence of malignancy; 5 months post-randomisation and at 1, 2 and 3 years post-recruitment; Degree of proteinuria; 1, 2 and 3 years post-recruitment; Changes in circulating CD20+ cells in peripheral blood; 5 months post-randomisation and at 1, 2 and 3 years post-recruitment; Changes in anti-graft Ab titres; 3 monthly to 3 years post-recruitment; Changes in T cell responsiveness to alloantigens; 3 monthly to 3 years post-recruitment
Publication(s)
Sorry, this information is not available
Result Reports
This is available on the Clinicaltrials.gov website
Gender
Both
Age Range
18 Years - 70 Years
Who Can Participate
Patients
Number of Participants
120
Participant Inclusion Criteria
  • Inclusion Criteria:
  • - Functioning kidney allograft (with estimated (e) GFR by MDRD >20) and be >6/12
  • post-transplantation
  • - Deteriorating allograft function as defined by linear regression of reciprocal
  • creatinine plot. Deterioration will be defined as a negative slope over at least the
  • preceding 3 months (with at least 6 creatinines included) with an adjusted r2 >0.35
  • and a p value of ≤0.05 compared to horizontal baseline. Deterioration will be
  • confirmed by reduction in Cockcroft-Gault (CG) eGFR over the same period (to exclude
  • increases in body mass as a cause of a negative slope on reciprocal creatinine plots)
  • OR significant proteinuria as assessed by a urine protein/creatinine ratio of ≥50
  • - CAN, by Banff '97 criteria, and/or transplant glomerulopathy on renal allograft
  • biopsy performed within 6/12 of enrolment
  • - Diffuse, linear C4d deposition on at least 25% of peritubular capillary (PTC) and/or
  • glomerular EC of renal transplant biopsy when assessed by immunoperoxidase or >50% of
  • PTC (alone) when assessed by immunofluorescence OR PTCitis OR glomerulitis with
  • combined PTC/g score of ≥2.
  • Exclusion Criteria:
  • - Ages below 18 years of age
  • - Suspicion of pregnancy confirmed by positive HCG pregnancy test
  • - Untreated ureteric obstruction on ultrasound of allograft
  • - History of acute allograft rejection in preceding 3/12
  • - History of MI in preceding 3/12
  • - History of malignancy in previous 5 years (excluding tumours limited to skin)
  • - Symptomatic IHD
  • - Recipient of simultaneous pancreas/kidney transplant
  • - Recipient of ABO-incompatible kidney
  • - Recipient who underwent an HLA desensitisation procedure prior to transplantation
  • - Evidence, on examination of renal allograft biopsy specimen, of recurrent or de-novo
  • disease (except IgA deposition in absence of mesangial proliferation)
  • - Evidence, on examination of renal allograft biopsy specimen, of CNI toxicity IF
  • ACCOMPANIED by mostly supra-therapeutic CNI trough levels in the 6 month period
  • preceding biopsy.
  • - Documented allergy to mouse or chimeric human/mouse proteins
  • - HepBsAg+, HepBcAb+, HCV Ab+ or HIV+.
Participant Exclusion Criteria
This is in the inclusion criteria above
Trial Location(s)
Research Site
Hull
HU3 2JZ
St. James University Hospital
Leeds
LS9 7TF
St. Helier Hospital
Carshalton
England
SM5 1AA
London
NW3 2PF
Manchester Royal Infirmary
Manchester
England
M13 9WL
GSK Investigational Site
Glasgow
G11 6NT
GSK Investigational Site
London
W12 0NN
University Hospital of Wales
Cardiff
Wales
CF14 4XW
East Kent Hospitals University Foundation Trust, Kent & Canterbury Hospital
Canterbury
CT1 3NG
University Hospital Birmingham
Birmingham
B15 2LN
King's College London, Guy's Hospital
London
SE 19RT
Trial Contact(s)
Primary Trial Contact
Anthony Dorling, PhD, FRCP
anthony.dorling@kcl.ac.uk
+44 7188 5880
Other Trial Contacts
Thanuja Weerasinghe
Thanuja.Weerasinghe@gstt.nhs.uk
+447787996198
Countries Recruiting
United Kingdom
Scientific Title
Randomised Trial of Anti-Cd20 in C4d+ Chronic Allograft Nephropathy
EudraCT Number
Not available for this trial
Funder(s)
  • Medical Research Council
  • Roche Pharma AG
Other Study ID Numbers
2006-002330-38
Sponsor(s)
King's College London
Key Dates

Recruitment Start Date

Jan 2007

Recruitment End Date

Dec 2018

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date Assigned

18 May 2007

Last Updated

22 Apr 2014